https://www.selleckchem.com/pr....oducts/BMS-794833.ht
Circulating tumor DNA (ctDNA) offers high sensitivity and specificity in metastatic cancer. However, many ctDNA assays rely on specific mutations in recurrent genes or require the sequencing of tumor tissue, difficult to do in a metastatic disease. The purpose of this study was to define the predictive and prognostic values of the whole-genome sequencing (WGS) of ctDNA in metastatic breast cancer (MBC). Plasma from 25 patients with MBC were taken at the baseline, prior to treatment (T, one week (T1) and two weeks (T2) after treatme
Like
Comment
Share
